Rapport Therapeutics (RAPP) Shares Outstanding (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Shares Outstanding data on file, last reported at $47.8 million in Q1 2026.

• Shares Outstanding for Q1 2026 came in at $47.8 million, up 30.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $47.8 million (up 30.99% YoY), and the FY2025 annual result was $47.8 million, up 30.6% from the prior year.
• Shares Outstanding held at $47.8 million in Q1 2026 per RAPP's latest filing, from $47.8 million in the prior quarter.
• Over five years, Shares Outstanding peaked at $47.8 million in Q1 2026 and troughed at $4.2 million in Q3 2023.
• A 4-year average of $28.6 million and a median of $36.5 million in 2024 frame the typical range for Shares Outstanding.
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding jumped 777.05% in 2024, then slipped 0.22% in 2025.
• A 4-year view of Shares Outstanding shows it stood at $4.2 million in 2023, then jumped by 777.05% to $36.6 million in 2024, then soared by 30.6% to $47.8 million in 2025, then grew by 0.07% to $47.8 million in 2026.
• Business Quant data shows RAPP's Shares Outstanding at $47.8 million in Q1 2026, $47.8 million in Q4 2025, and $47.7 million in Q3 2025.